After a secondary it takes a while for the market to digest the shares. Look for a low next week, especially since they did not clear the offering in one day.
Those lucky to hit the exact bottom will realize a neat two point gain in a month. Good timing in the middle of a bull run.
yep, very positive - and the S&P rates it still a buy w/ higher price target, and usual biotech bear Zacks is quite positive. I remember they were so negative on Amylin forever. And this CEO is one of the best!
If you look back at March 2012, you'll see a big volume spike. Elan sold a massive chunk then, and now they're selling remaining 7M+ shares they have. And what's more important, the stock dipped a buck or so March 2012 after that sell, and then bounce right back up to higher than it was only a few weeks after. So based on that and the earnings report, I scooped up some shares here in premarket. Nothing major, mind you, for I'm just a small potato in this game.